AER 1455090 is a non-interventional program case, received on 26/Aug/2014 from a consumer via company 
representative and concerns a patient of unspecified demographics who developed progressive multifocal 
leukoencephalopathy while participated in(b) (6)  Studies specifically designed for Compensation/re-
imbursement schemes (multiple products) and being treated with rituximab (Rituxan).
No medical history, concurrent illness, concomitant medications or past drugs were reported.
On an unspecified date, the patient started rituximab for an unknown indication.  Dosage regimen for rituximab was
not reported.  Later, patient developed progressive multifocal leukoencephalopathy.
At the time of this report, the outcome of event progressive multifocal leukoencephalopathy and therapy status of 
rituximab was not reported.
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 252 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The reporter did not assess the causality of event progressive multifocal leukoencephalopathy with rituximab.
The company assessed the causality of medically significant event progressive multifocal leukoencephalopathy as 
related with rituximab.
No further information was provided.